Samjin Pharmaceutical Pursues Technology Transfer Valued at 800 Billion Won—Shares Poised for Revaluation

Samjin Pharmaceutical is advancing the technology transfer of its chronic urticaria drug candidate SJN314, valued at 800 billion won ($610 million), with expectations for a share price revaluation and a strategic shift from generics to innovative drugs.